Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Review on Targeted Treatment of Patients with Advanced-Stage Renal Cell Carcinoma: A Medical Oncologist's Perspective

  • Tanriverdi, Ozgur (Department of Medical Oncology, Mugla Sitki Kocman University Education and Research Hospital)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Renal cell carcinomas make up 3% of all cancers and one in four patients is metastatic at time of diagnosis. This cancer is one of the most resistant to cytotoxic chemotherapy. Studies have shown that the efficiency of interferon-alpha and/or interleukin-2 based immune therapies is limited in patients with metastatic renal cell carcinoma but latest advances in molecular biology and genetic science have resulted in better understanding of its biology. Tumor angiogenesis, tumor proliferation and metastasis develop by the activation of signal message pathways playing a role in the development of renal cell carcinomas. Better definition of these pathways has caused an increase in preclinic and clinical studies into target directed treatment of renal cell carcinoma. Many recent studies have shown that numerous anti-angiogenic agents have marked clinical activity. In this article, the focus is on general characteristics of molecular pathways playing a major role in renal cell carcinoma, reviewing clinical information onagents used in the target directed treatment of metastatic lesions.

Keywords

References

  1. Atkins MB, Hidalgo M, Stadler WM, et al (2004). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol, 22, 909-18. https://doi.org/10.1200/JCO.2004.08.185
  2. Bhargava P, Esteves B, Al-Adhami M, et al (2010). Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT) [abstract 4599]. J Clin Oncol, 28, 366. https://doi.org/10.1200/JCO.2009.26.8292
  3. Bracarda S, Bellmunt J, Melichar B, et al (2011). Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-$\alpha$2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int, 107, 214-9. https://doi.org/10.1111/j.1464-410X.2010.09707.x
  4. Brugge JS, MvCormick F (1999). Cell regulation intracellular networking. Curr Opin Cell Biol, 11, 173-6. https://doi.org/10.1016/S0955-0674(99)80022-2
  5. Bukowski RM (2001). Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol, 19, 148-54.
  6. Choueiri TK, Pal SK, McDermott DF, et al (2012). Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol, 30, 364. https://doi.org/10.1200/JCO.2012.43.0504
  7. Drevs J, Muller-Driver R, Wittig C, et al (2002). PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res, 62, 4015-22.
  8. Dutcher JP, de Souza P, McDermott D, et al (2009). Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol, 26, 202-9. https://doi.org/10.1007/s12032-009-9177-0
  9. Eisen T, Joensuu H, Nathan PD, et al (2012). Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol, 13, 1055-62. https://doi.org/10.1016/S1470-2045(12)70364-9
  10. Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, 125-34. https://doi.org/10.1056/NEJMoa060655
  11. Escudier B, Pluzanska A, Koralewski P, et al (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet, 370, 2103-11. https://doi.org/10.1016/S0140-6736(07)61904-7
  12. Escudier B, Szczylik C, Hutson TE, et al (2009). Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 27, 1280-9. https://doi.org/10.1200/JCO.2008.19.3342
  13. Escudier B, Eisen T, Stadler WM, et al (2009). Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 27, 3312-8. https://doi.org/10.1200/JCO.2008.19.5511
  14. Escudier B, Bellmunt J, Negrier S, et al (2010). Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol, 28, 2144-50. https://doi.org/10.1200/JCO.2009.26.7849
  15. Escudier B, Kataja V (2010). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 137-9. https://doi.org/10.1093/annonc/mdq206
  16. Escudier B, Osanto S, Ljungberg B, et al (2012). Multidiciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat Rev, 38, 127-32. https://doi.org/10.1016/j.ctrv.2011.05.006
  17. Escudier BJ, Porta C, Bono P, et al (2012). Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a rendomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)- PISCES study, NCT 01064310. J Clin Oncol, 30, 4502.
  18. Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76. https://doi.org/10.1038/nm0603-669
  19. Foon KA, Yang XD, Weiner LM, et al (2004). Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys, 58, 984-90. https://doi.org/10.1016/j.ijrobp.2003.09.098
  20. Frost P, Moatamed F, Hoang B, et al (2004). In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multipl myeloma cells in a xenograft model. Blood, 104, 4181-7. https://doi.org/10.1182/blood-2004-03-1153
  21. Gore ME, Hariharan S, Porta C, et al (2011). Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 117, 501-9. https://doi.org/10.1002/cncr.25452
  22. Hanna SC, Heatcote SA, Kim WY (2008). mTOR pathway in renal cell carcinoma. Expert Rev Anticancer, 8, 283-92. https://doi.org/10.1586/14737140.8.2.283
  23. Harari PM (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer, 11, 689-708. https://doi.org/10.1677/erc.1.00600
  24. Hicklin DJ, Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor-growth and angiogenesis. J Clin Oncol, 23, 1011-27.
  25. Hudes GR, Carducci M, Tomczak P, et al (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 356, 2271-81. https://doi.org/10.1056/NEJMoa066838
  26. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  27. Kuenen BC, Levi M, Meijers JC, et al (2002). Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol, 22, 1500-5. https://doi.org/10.1161/01.ATV.0000030186.66672.36
  28. Ljungberg B, Campbell SC, Cho HY, et al (2011). The epidemiology of renal cell carcinoma. Eur Urol, 60, 615-21. https://doi.org/10.1016/j.eururo.2011.06.049
  29. Lundberg AS, Weinberg RA (1999). Control of the cell cycle and apoptosis. Eur J Cancer, 35, 1886-94. https://doi.org/10.1016/S0959-8049(99)00292-0
  30. Mendel DB, Laird AD, Xin X, et al (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynmic relationship. Clin Cancer Res, 9, 327-37.
  31. Mendelsohn J, Baselga J (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21, 2787-99. https://doi.org/10.1200/JCO.2003.01.504
  32. Motzer RJ, Mazumdar M, Bacik J, et al (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17, 2530-40.
  33. Motzer RJ, Amato R, Todd M, et al (2003). Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs, 21, 99-101. https://doi.org/10.1023/A:1022928612511
  34. Motzer RJ, Bacik J, Schwartz LH, et al (2004). Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol, 22, 454-63.
  35. Motzer RJ, Rini BI, Bukowski RM, et al (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295, 2516-24. https://doi.org/10.1001/jama.295.21.2516
  36. Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24. https://doi.org/10.1200/JCO.2005.02.2574
  37. Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24. https://doi.org/10.1056/NEJMoa065044
  38. Motzer RJ, Escudier B, Oudard S, et al (2008). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial. Lancet, 72, 449-56.
  39. Motzer RJ, Escudier B, Oudard S, et al (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer, 116, 4256-65. https://doi.org/10.1002/cncr.25219
  40. Motzer RJ, Hutson TE, Olsen MR, et al (2011). Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. J Clin Oncol, 29, 308. https://doi.org/10.1200/JCO.2010.32.6082
  41. Motzer RJ, Hudson TE, Reeves J, et al (2012). Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mrcc): results of the COMPARZ trial. Presented at: 2012 European Society for Medical Oncology; Vienna, Austria; October 1, 20120. Abstract LBA 8. ESMO.
  42. Motzer RJ, Nosov D, Eisen T, et al (2012). Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol, 30, 4501. https://doi.org/10.1200/JCO.2012.43.6758
  43. Negrier S, Gravis G, Perol D, et al (2011). Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomized phase 2 trial. Lancet Oncol, 12, 673-80. https://doi.org/10.1016/S1470-2045(11)70124-3
  44. Presta LG, Chen H, O'Connor SJ, et al (1997). Humanization of an anti-vascular endothelian growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 57, 4593-9.
  45. Price JT, Wilson HM, Haites NE (1996). Epidermal growth factor (EGF) increases the in vitro invasion, motility, and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer, 32, 1977-82. https://doi.org/10.1016/0959-8049(96)00207-9
  46. Radulovic S, Bjelogrlic SK (2007). Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON, 12, 151-62.
  47. Ratain MJ, Eisen T, Stadler WM, et al (2006). Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 2505-12. https://doi.org/10.1200/JCO.2005.03.6723
  48. Rini B (2005). SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin Genitourin Cancer, 4, 175-80. https://doi.org/10.3816/CGC.2005.n.029
  49. Rini B (2007). Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res, 13, 1098-106. https://doi.org/10.1158/1078-0432.CCR-06-1989
  50. Rini B, Escudier B, Tomczak P, et al (2011). Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. ASCO 2011 [abstract:4503].
  51. Rini BI (2005). VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist, 10, 191-7. https://doi.org/10.1634/theoncologist.10-3-191
  52. Rini BI, Halabi S, Rosenberg JE, et al (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with renal cell carcinoma: CALGB 90206. J Clin Oncol, 26, 5422-8. https://doi.org/10.1200/JCO.2008.16.9847
  53. Rini BI, Halabi S, Rosenberg JE, et al (2010). Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monothreapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol, 28, 2137-43. https://doi.org/10.1200/JCO.2009.26.5561
  54. Rini BI, Escudier B, Tomczak P, et al (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet, 378, 1931-9. https://doi.org/10.1016/S0140-6736(11)61613-9
  55. Rini BI, Grunwald V, Fishman MN, et al (2012). Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol, 30, 4503.
  56. Sternberg CN, Davis ID, Mardiak J, et al (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol, 28, 1061-68. https://doi.org/10.1200/JCO.2009.23.9764
  57. Xu L, Tong R, Cochran DM, et al (2005). Blocking platelet-derived growth factor-D/ platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res, 65, 5711-19. https://doi.org/10.1158/0008-5472.CAN-04-4313
  58. Wells A (1999). EGF receptor. Int J Biochem Cell Biol, 31, 637-43. https://doi.org/10.1016/S1357-2725(99)00015-1
  59. Willhelm SM, Carter C, Tang L, et al (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEF/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-109. https://doi.org/10.1158/0008-5472.CAN-04-1443
  60. Yang JC, Haworth L, Sherry RM, et al (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349, 427-34. https://doi.org/10.1056/NEJMoa021491
  61. Yazici S, Kiziloz H, Ozen H (2011). Recent advancements in the targeted therapy of metastatic kidney cancer. Uroonkoloji Bulteni, 3, 41-51.

Cited by

  1. Asparagus Racemosus Leaf Extract Inhibits Growth of UOK 146 Renal Cell Carcinoma Cell Line: Simultaneous Oncogenic PRCCTFE3 Fusion Transcript Inhibition and Apoptosis Independent Cell Death vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.1937
  2. Targeting EGFL7 Expression through RNA Interference Suppresses Renal Cell Carcinoma Growth by Inhibiting Angiogenesis vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3045
  3. ST6Gal-I Predicts Postoperative Clinical Outcome for Patients with Localized Clear-cell Renal Cell Carcinoma vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10217
  4. Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma vol.9, pp.5, 2014, https://doi.org/10.3892/mmr.2014.2046